The case for & against
Bull & Bear analysis
GlaxoSmithKline plc (NYSE: GSK) is a global healthcare company primarily engaged in the research, development, and production of pharmaceuticals, vaccines, and consumer healthcare products. The firm is strategically positioned within high-growth segments such as oncology and respiratory medicines, with a strong emphasis on specialty therapies which are critical to its growth trajectory. GSK aims to address unmet medical needs through its evolving pipeline, specifically targeting therapeutic areas like infectious diseases, oncology, and respiratory health.
Bull says
- ↑Specialty medicines sales rose 17% YoY, accounting for 40% of overall revenue
- ↑Operating cash flow of £8.9 B in 2025 supports R&D and share buybacks
- ↑$30 B R&D and advanced manufacturing investment over five years to expand pipeline
- ↑Long-acting HIV injectables now drive 75% of specialty segment growth
- ↑Dividend yield at 1.08% and active buybacks enhance shareholder returns
- ↑High profitability and stable momentum underpin resilient stock performance
Bear says
- ↓Medicare redesign from the IRA could reduce revenues by up to £500 M
- ↓General medicines sales declined 9% amid rising competition
- ↓Elevated short interest suggests potential downward pressure on shares
- ↓Negative analyst revisions and weak revenue growth metrics dampen outlook
- ↓Regulatory and approval delays (e.g. BlenRep) pose pipeline execution risk
- ↓Buyback capacity could shrink if operating cash flow weakens
Investment themes with GSK
Stable developed market with finance and pharmaceuticals
Value-oriented stocks outside domestic markets
Earnings Call · Q2 2025 · Mgmt. Guidance
Transcript signals
Bull points
- Our HIV portfolio continues to deliver exceptional growth of 12% in the quarter. Nine points of growth came from strong patient demand for our long-acting injectables and Devato. And three points came from customer stocking patterns and tender phasing.
- We saw demand grow across all regions and major markets, particularly the U.S., which grew 14% through double-digit demand growth and where we saw not only total share gain uphasing the competition, but Cabinuvr consistently gaining at least 70% of product switches from competitors.
- Devato continue to deliver strong performance of 23% and our long-acting injectables, Cabinuvr and Apertude, delivered robust growth at 46% and 50% respectively.
Bear points
- Cost of sales for the quarter grew 7% ahead of sales due to pricing impacts and supply chain optimization charges.
- the Q2 fall in the gross margin was predominantly driven by lower RAR benefits year on year and by charges associated with supply chain optimization.
- net debt is expected to include almost £3 billion of outflows relating to the settlement of Zantac, the completion of FMS Furman and the Hengrui collaboration, together with the ongoing share buyback.